Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Agency for Care Effectiveness (ACE)
Record ID 32018014190
English
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/drug-guidance/axicabtagene-ciloleucel--for-relapsed-or-refractory-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapy
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Lymphoma
- Biological Products
- Lymphoma, Large B-Cell, Diffuse
- Immunotherapy, Adoptive
- Antineoplastic Agents, Immunological
- Receptors, Chimeric Antigen
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.